<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study was designed to evaluate the effect of low-dose Ara-C in the treatment of refractory, atypical <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The subjects were 33 patients (19 <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 9 MDS, 3 atypical <z:hpo ids='HP_0001909'>leukemia</z:hpo> and 2 unclassified <z:hpo ids='HP_0001909'>leukemia</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>The age range was 19 to 84 years with a mean age of 51.5 years </plain></SENT>
<SENT sid="3" pm="."><plain>We administered low-dose Ara-C (5-10 mg/m2/12 h s.c. or i.v.) for 13 to 35 days with a mean of 16.7 days </plain></SENT>
<SENT sid="4" pm="."><plain>Complete remission and partial remission were obtained in 8 of 31 (25.8%) and in 9 of 31 (29.0%) respectively </plain></SENT>
<SENT sid="5" pm="."><plain>A high response rate was found in M2 types showing a tendency for mature and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> according to the FAB classification </plain></SENT>
<SENT sid="6" pm="."><plain>In our cases, severe <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> in peripheral blood as a result of Ara-C was observed before <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis recurred </plain></SENT>
<SENT sid="7" pm="."><plain>From the above results, the mechanism of low-dose Ara-C may induce remission by a cytotoxic rather than a differentiation effect </plain></SENT>
<SENT sid="8" pm="."><plain>This treatment can be offered to patients with refractory, atypical <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with limited toxicity </plain></SENT>
</text></document>